In conversation with Will Hind of Alpharmaxim
Applying behavioural science in biopharma
In this episode of NPTV Unscripted, Alpharmaxim founder and CEO William Hind talks with Peter Llewellyn about the recent publication of Parkinson’s: Beyond the hidden barriers to adoption of new treatments.
Watch now on NetworkPharma.tv to learn about the genesis of the project, our work with Aston University, and how the new white paper can help transform therapeutic approaches.
Why this matters now
Despite unprecedented innovation in Parkinson’s and other therapy areas, the adoption of new treatments is often hindered by entrenched behaviours, clinical mindsets, and hidden psychological barriers. Our research identifies 17 universal barriers to prescribing change, offering actionable insights for pharmaceutical and biotech companies launching new therapies.
What’s inside the white paper:
A gold-standard framework (H-BIT) for mapping and overcoming behavioural barriers
Strategic guidance for accelerating product adoption and reducing launch risk
Evidence-based interventions that go beyond traditional communications, ensuring your innovations reach the patients who need them most
Real-world examples and a stepwise approach to driving meaningful behaviour change
Key for Parkinson’s – but relevant everywhere
While this white paper focuses on Parkinson’s, the principles and validated framework are universally applicable. Whether you’re launching in neurology, oncology, or any other therapy area, these insights can be tailored to your context to maximise impact and ROI.